Anti-tumor Necrosis Factor Therapy Effect on Takayasu Arteritis
Trial Snapshot
- Phase
- Phase 2
- Enrollment
- 11
- Locations
- 1
- Primary Endpoint
- remission induction at 30 weeks
Study Overview
Brief Summary
Clinical study of anti-tumor necrosis factor therapy in patients with Takayasu arteritis.
This study is single arm (anti Tumor necrosis factor therapy only) clinical trial. Enrolled patients will be 11
Detailed Description
Clinical study of anti-tumor necrosis factor therapy in patients with Takayasu arteritis.
This study is single arm (anti Tumor necrosis factor therapy only) clinical trial. Enrolled patients will be 11 patients with active takayasu's arteritis
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •active takayasu's arteritis
Exclusion Criteria
- •active Tuberculosis
- •Liver function abnormality
- •heart failure ( New York Heart Association III - IV)
- •patients were not consented
Arms & Interventions
experimental group
anti Tumor necrosis factor treatment group : treatment with remicade 5mg/kg as scheduled (0, 2, 6, 14, 22, 30, 38, 46, 54weeks).
evaluation of response at 30weeks by PET CT, acute phase reactants, symptom
No placebo group
Intervention: remicade (anti tumor necrosis factor inhibitor) (Drug)
Outcomes
Primary Outcomes
remission induction at 30 weeks
Time Frame: 30 weeks
Secondary Outcomes
No secondary outcomes reported